

Drug Monograph

Drug/Drug **Abilify Maintena™ (aripiprazole) kit / Atypical**
Class: **Antipsychotic**
Prepared for: MO HealthNet
Prepared by: Xerox Heritage, LLC

New Criteria

Revision of Existing Criteria

Executive Summary

Purpose:	The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit or require prior authorization for use.
Dosage Forms:	Abilify Maintena™ is now available in a single-use dual chamber syringe for extended-release injection containing 300 mg or 400 mg of aripiprazole respectively.
Manufacturer:	Otsuka America Pharmaceutical, Inc. Rockville, MD 20850
Indications:	Abilify Maintena™ is indicated for the treatment of schizophrenia.
Costs:	\$1200.22 per 300 mg Abilify Maintena™ kit and \$1600.30 per 400 mg Abilify Maintena™ kit. Maximum Allowable Cost
Summary of Findings:	The Division recommends adding this drug to the current Atypical Antipsychotics clinical edit.
Status Recommendation:	<input type="checkbox"/> Prior Authorization (PA) Required <input type="checkbox"/> Open Access <input type="checkbox"/> Fiscal Edit <input checked="" type="checkbox"/> Clinical Edit
Type of PA Criteria:	<input type="checkbox"/> Increased Risk of ADE <input type="checkbox"/> Non-Preferred Agent <input checked="" type="checkbox"/> Appropriate Indications <input type="checkbox"/> No PA Required

Prepared By: Luke Boehmer, Pharm. D.
Date: May 1, 2015